Paglalarawan

Facilitated importation of Cuvitru for patients in countries where the drug may be difficult to source locally. The service handles regulatory compliance and logistics for patient-named medicine access.

Pinakamainam para sa

patients with limited local access, international drug procurement, regulatory-compliant medical import at rare disease patient support

Paglalarawan

Cuvitru (Immune Globulin Subcutaneous [Human], 20% Solution) is an immunology medication used as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients aged 2 years and older. This 20% liquid solution is a plasma-derived therapy administered via subcutaneous infusion, designed to replace functioning antibodies in patients with antibody deficiencies. It offers a customizable treatment schedule ranging from daily to biweekly and supports infusion rates of up to 60 mL/hr per site, allowing for faster and more flexible administration compared to lower-concentration immunoglobulin products.

Pinakamainam para sa

primary immunodeficiency treatment, pediatric patients 2 and older, subcutaneous immunoglobulin therapy at flexible infusion schedules

Paglalarawan

Cuvitru is a 20% liquid SCIG indicated for Primary Humoral Immunodeficiency (PI) in patients 2 years and older. It supports fast infusion rates up to 60 mL/hr per site and offers flexible dosing regimens.

Pinakamainam para sa

pediatric PI patients, fast infusion rates, flexible dosing at subcutaneous IgG